Pooled Analysis of Impact of TP53 Mutations on Efficacy of Venetoclax + Azacitidine in Patients With AML and Poor-Risk Cytogenetics

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
In older/unfit patients with AML and poor-risk cytogenetics, frontline treatment with venetoclax plus azacitidine improved DoR and OS vs Aza in wild-type but not mutated TP53.
Format: Microsoft PowerPoint (.ppt)
File Size: 562 KB
Released: December 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings